Tag Archives: PBS
Sponsors struggle with Ministerial discretion
The 2017 Medicines Australia Strategic Agreement with the Australian Government extended the existing five-year anniversary statutory price reduction (SPR) of 5% for F1 medicines and introduced new SPRs for drugs that have been listed for ten years and fifteen years … Continue reading
Life Saving Drugs Program: new lease on life, or on life support?
Last week saw the release of the final report of the post-market review into the Life Saving Drugs Program (LSDP), including a response to the report released by the Australian Government. The Life Saving Drugs Program currently provides subsidised access … Continue reading
Dr Greg Pearce – Time to support biosimilars
Dr Greg Pearce, from our Regulatory Services team, has written a follow-up article for Pharma in Focus on biosimilars. Dr Pearce’s first article focussed on the challenges biosimilars pose for the Australian medicines industry. This second article looks at the … Continue reading
Defining value in the MBS Review
In May 2015 the Federal Government announced a review of the Medicare Benefits Schedule (MBS) with a view to bringing the MBS up-to-date and increase the value derived from the more than 5,700 listed items. The announcement of this review … Continue reading
PBS Flies Under the Radar
In the week leading up to Wayne Swan handing down his fourth Budget, tension built in the Health sector, especially amongst those in the medicines business. Now many are wondering what all the fuss was about. Continue reading
The Top 5 – Budget Highlights for Health
Treasurer Wayne Swan’s first Budget under Julia Gillard’s leadership has some important implications for Health. We analyse the top five… Continue reading
